MX2022007768A - Dextrometadona como un tratamiento de modificación de enfermedad para trastornos y enfermedades neuropsiquiátricas. - Google Patents

Dextrometadona como un tratamiento de modificación de enfermedad para trastornos y enfermedades neuropsiquiátricas.

Info

Publication number
MX2022007768A
MX2022007768A MX2022007768A MX2022007768A MX2022007768A MX 2022007768 A MX2022007768 A MX 2022007768A MX 2022007768 A MX2022007768 A MX 2022007768A MX 2022007768 A MX2022007768 A MX 2022007768A MX 2022007768 A MX2022007768 A MX 2022007768A
Authority
MX
Mexico
Prior art keywords
dextromethadone
diseases
disease
neuropsychiatric disorders
modifying treatment
Prior art date
Application number
MX2022007768A
Other languages
English (en)
Inventor
Charles E Inturrisi
Paolo L Manfredi
Andrea Mattarei
Martin Sara De
Jacopo Sgrignani
Andrea Cavalli
Original Assignee
Univ Of Padova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Padova filed Critical Univ Of Padova
Publication of MX2022007768A publication Critical patent/MX2022007768A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Métodos y composiciones para modificar el curso y gravedad de trastornos neuropsiquiátricos; el método incluye administrar una composición a un sujeto que sufre de un trastorno neuropsiquiátrico, en donde la composición incluye una sustancia seleccionada de dextrometadona, metabolitos de la dextrometadona, d-metadol, d-alfa-acetilmetadol, d-alfa-normetadol, l-alfa-normetadol, y sales farmacéuticamente aceptables del mismo.
MX2022007768A 2020-01-03 2020-12-30 Dextrometadona como un tratamiento de modificación de enfermedad para trastornos y enfermedades neuropsiquiátricas. MX2022007768A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062956839P 2020-01-03 2020-01-03
US202062963874P 2020-01-21 2020-01-21
US202062993188P 2020-03-23 2020-03-23
US202063010391P 2020-04-15 2020-04-15
US202063031785P 2020-05-29 2020-05-29
PCT/US2020/067498 WO2021138443A1 (en) 2020-01-03 2020-12-30 Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases

Publications (1)

Publication Number Publication Date
MX2022007768A true MX2022007768A (es) 2022-09-27

Family

ID=76687448

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007768A MX2022007768A (es) 2020-01-03 2020-12-30 Dextrometadona como un tratamiento de modificación de enfermedad para trastornos y enfermedades neuropsiquiátricas.

Country Status (12)

Country Link
US (1) US20230017786A1 (es)
EP (1) EP4085044A1 (es)
JP (1) JP2023509484A (es)
KR (1) KR20220164470A (es)
CN (1) CN115397804A (es)
AU (1) AU2020419181A1 (es)
BR (1) BR112022013160A2 (es)
CA (1) CA3166254A1 (es)
MX (1) MX2022007768A (es)
TW (1) TW202140415A (es)
UY (1) UY39007A (es)
WO (1) WO2021138443A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US9468611B2 (en) * 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
WO2018144551A2 (en) * 2017-01-31 2018-08-09 Manfredi Paolo L Compounds for treatment or prevention of disorders of the nervous system and symptoms and manifestations thereof, and for cyto-protection against diseases and aging of cells, and symptoms and manifestations thereof
RU2019143573A (ru) * 2017-05-25 2021-06-28 Глитек Ллс. Комбинированная терапия нейропсихиатрических расстройств, восприимчивых к антагонисту nmdar
EP3917619A4 (en) * 2019-01-30 2022-10-26 University of Padova STRUCTURALLY MODIFIED OPIOIDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND CONDITIONS

Also Published As

Publication number Publication date
BR112022013160A2 (pt) 2022-11-08
WO2021138443A1 (en) 2021-07-08
JP2023509484A (ja) 2023-03-08
UY39007A (es) 2021-07-30
KR20220164470A (ko) 2022-12-13
TW202140415A (zh) 2021-11-01
CN115397804A (zh) 2022-11-25
US20230017786A1 (en) 2023-01-19
CA3166254A1 (en) 2021-07-08
EP4085044A1 (en) 2022-11-09
AU2020419181A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
CR20220363A (es) Compuestos tricíclicos sustituidos
MX2020002652A (es) Esteroides neuroactivos y su método de uso.
PH12020551425A1 (en) Rimegepant for cgrp related disorders
MD4539B1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
MX2020009062A (es) Piperidinil-3-(ariloxi)propanamidas y propanoatos.
PH12020551501A1 (en) Oxadiazole transient receptor potential channel inhibitors
MX2022006807A (es) Análogos de rapamicina y usos de estos.
CR20210212A (es) Composiciones y métodos para tratar trastornos mejorados por medio de activación de receptor muscarínico
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
PH12019501968A1 (en) PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES
MX2022002597A (es) Métodos de tratamiento de la epilepsia usando los métodos.
MX2021007247A (es) Derivados de rapamicina.
MX2023001071A (es) Tratamiento de la migraña.
WO2021100029A3 (en) Prodrugs of fulvestrant
MX2022013650A (es) Imidazopirimidinas como moduladores de il-17.
MX2022000203A (es) Composiciones de liberacion sostenida de endoxifeno.
ZA202206266B (en) Pd-l1 antagonist compound
MX2023002283A (es) Antagonista cristalino del receptor edg-2 y metodos de fabricacion.
MX2022007768A (es) Dextrometadona como un tratamiento de modificación de enfermedad para trastornos y enfermedades neuropsiquiátricas.
MX2022000287A (es) Composición de inhibidor micromolécular de pi4kiiia, método de preparación y uso.
MX2021012248A (es) Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos.
WO2019014322A8 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
MX2022012404A (es) Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas.